Condition: Pancreatic Carcinoma · Sponsor: CEBIOTEX
The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer
This description comes directly from the study's public registry record.
A Responsible Person Designated by the Sponsor · +34 93 434 44 12 · investigacion@mfar.net
Anna Huguet, Ph.D. · +34 93 434 44 12 · ahuguet@cebiotex.com
Always discuss trial participation with your own doctor first.
| Hospital Clínico y Provincial de Barcelona | Barcelona, Catalonia, Spain | Recruiting |
| H. Clínico San Carlos | Madrid, Madrid, Spain | Recruiting |
| H.U. Virgen del Rocío | Seville, Sevilla, Spain | Recruiting |
| H. Clínico Univ. de Valencia | Valencia, Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06538857